A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Quadrivalent Influenza Vaccine in Adults ≥65 Years of Age
Latest Information Update: 17 Nov 2025
At a glance
- Drugs Influenza vaccine quadrivalent Seqirus (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Registrational; Therapeutic Use
- Sponsors Seqirus
Most Recent Events
- 10 Jul 2025 Status changed from recruiting to active, no longer recruiting.
- 24 Jun 2025 Status changed from active, no longer recruiting to recruiting.
- 03 Feb 2025 Status changed from recruiting to active, no longer recruiting.